SERT-to-DAT ratios in early Parkinson’s disease do not correlate with the development of dyskinesias

EJNMMI Research

Table 2 Mean specific to non-specific [¹²³ I]β-CIT binding ratios (BP _ND ) (mean ± SD) and SERT-to-DAT ratios

Region of interest	PD_NDYS(n= 27)	PD_DYS(n= 23)	P value
Striatum, whole	4.02 ± 0.30	4.16 ± 0.24	0.66
Striatum, most affected side	3.43 ± 0.31	3.59 ± 0.27	0.57
Caudate nucleus, whole	6.02 ± 0.30	6.33 ± 0.25	0.52
Caudate nucleus, most affected side	5.34 ± 0.34	5.73 ± 0.28	0.43
Putamen, whole	3.03 ± 0.32	3.00 ± 0.26	0.93
Putamen, most affected side	2.39 ± 0.33	2.43 ± 0.28	0.82
Midbrain	1.05 ± 0.40	1.14 ± 0.35	0.41
Midbrain/Putamen, whole	0.33 ± 0.32	0.35 ± 0.36	0.48
Midbrain/Putamen most affected side	0.42 ± 0.32	0.44 ± 0.38	0.67
Midbrain/Caudate, whole	0.17 ± 0.32	0.17 ± 0.32	0.88
Midbrain/Caudate, most affected side	0.19 ± 0.34	0.19 ± 0.37	0.97
Midbrain/Striatum, whole	0.25 ± 0.31	0.26 ± 0.34	0.75
Midbrain/Striatum, most affected side	0.29 ± 0.31	0.30 ± 0.38	0.87

SERT serotonin transporter, DAT dopamine transporter, SD standard deviation, PD Parkinson’s disease, PD _NDYS PD patients subgroup that did not develop dyskinesias, PD _DYS PD patients subgroup that developed dyskinesias.